RESUMO
Resistance to clinical malaria takes years to develop even in hyperendemic regions and sterilizing immunity has rarely been observed. To evaluate the maturation of the host response against controlled repeat exposures to P. falciparum (Pf) NF54 strain-infected mosquitoes, we systematically monitored malaria-naïve participants through an initial exposure to uninfected mosquitoes and 4 subsequent homologous exposures to Pf-infected mosquitoes over 21 months (n = 8 males) (ClinicalTrials.gov# NCT03014258). The primary outcome was to determine whether protective immunity against parasite infection develops following repeat CHMI and the secondary outcomes were to track the clinical signs and symptoms of malaria and anti-Pf antibody development following repeat CHMI. After two exposures, time to blood stage patency increases significantly and the number of reported symptoms decreases indicating the development of clinical tolerance. The time to patency correlates positively with both anti-Pf circumsporozoite protein (CSP) IgG and CD8 + CD69+ effector memory T cell levels consistent with partial pre-erythrocytic immunity. IFNγ levels decrease significantly during the participants' second exposure to high blood stage parasitemia and could contribute to the decrease in symptoms. In contrast, CD4-CD8 + T cells expressing CXCR5 and the inhibitory receptor, PD-1, increase significantly after subsequent Pf exposures, possibly dampening the memory response and interfering with the generation of robust sterilizing immunity.
Assuntos
Malária Falciparum , Plasmodium falciparum , Proteínas de Protozoários , Humanos , Malária Falciparum/imunologia , Malária Falciparum/parasitologia , Malária Falciparum/sangue , Plasmodium falciparum/imunologia , Masculino , Proteínas de Protozoários/imunologia , Animais , Adulto , Anticorpos Antiprotozoários/imunologia , Anticorpos Antiprotozoários/sangue , Interferon gama/metabolismo , Interferon gama/imunologia , Feminino , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Adulto Jovem , Linfócitos T CD8-Positivos/imunologia , Mosquitos Vetores/parasitologia , Mosquitos Vetores/imunologia , Anopheles/parasitologiaRESUMO
A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen. Safety, immunogenicity, and VE of a three-dose regimen were assessed in adults in Balonghin, Burkina Faso in a two-component study: an open-label dose escalation trial with 32 participants followed by a double-blind, randomized, placebo-controlled trial (RCT) with 80 participants randomized to receive three doses of 2.7 × 106 PfSPZ (N = 39) or normal saline (N = 41) just before malaria season. To clear parasitemia, artesunate monotherapy was administered before first and last vaccinations. Thick blood smear microscopy was performed on samples collected during illness and every 4 weeks for 72 weeks after last vaccinations, including two 6-month malaria transmission seasons. Safety outcomes were assessed in all 80 participants who received at least one dose and VE for 79 participants who received three vaccinations. Myalgia was the only symptom that differed between groups. VE (1 - risk ratio; primary VE endpoint) was 38% at 6 months (P = 0.017) and 15% at 18 months (0.078). VE (1 - hazard ratio) was 48% and 46% at 6 and 18 months (P = 0.061 and 0.018). Two weeks after the last dose, antibodies to P. falciparum circumsporozoite protein and PfSPZ were higher in protected versus unprotected vaccinees. A three-dose regimen of PfSPZ Vaccine demonstrated safety and efficacy against malaria infection in malaria-experienced adults.
Assuntos
Esporozoítos , Vacinas , Humanos , AnimaisRESUMO
Enzyme-linked immunosorbent assays (ELISAs) remain the gold standard for measuring antibodies, but are time-consuming and use significant amounts of precious sample and reagents. Protein microarrays represent an appealing alternative, particularly for studies focused on large gene families such as those encoding variant surface antigens in the malaria parasite Plasmodium falciparum. Such microarrays represent an ideal high-throughput platform to study antibody responses to hundreds of malaria parasite variant surface antigens at once, providing critical insights into the development of natural immunity to malaria. We describe the essential background and approach to run an assay using a P. falciparum microarray populated with variant surface antigens. This allows the user to define serologic profiles and identify serodominant antigens that represent promising targets for vaccine or therapeutic development.
Assuntos
Malária Falciparum , Malária , Anticorpos Antiprotozoários , Formação de Anticorpos , Antígenos de Protozoários , Antígenos de Superfície/metabolismo , Eritrócitos/metabolismo , Humanos , Malária Falciparum/parasitologia , Plasmodium falciparum/metabolismo , Análise Serial de Proteínas , Proteínas de Protozoários/metabolismoRESUMO
Direct venous inoculation of 3.2 × 103 aseptic, purified, cryopreserved, vialed Plasmodium falciparum (Pf) strain NF54 sporozoites, PfSPZ Challenge (NF54), has been used for controlled human malaria infection (CHMI) in the United States, 4 European countries, and 6 African countries. In nonimmune adults, this results in 100% infection rates. We conducted a double-blind, randomized, dose-escalation study to assess the infectivity of the 7G8 clone of Pf (PfSPZ Challenge [7G8]). Results showed dose-dependent infectivity from 43% for 8 × 102 PfSPZ to 100% for 4.8 × 103 PfSPZ. PfSPZ Challenge (7G8) will allow for more complete assessment by CHMI of antimalarial vaccines and drugs.
Assuntos
Relação Dose-Resposta Imunológica , Vacinas Antimaláricas/imunologia , Malária Falciparum/prevenção & controle , Malária Falciparum/parasitologia , Plasmodium falciparum/imunologia , Esporozoítos/imunologia , Administração Intravenosa , Adulto , Feminino , Humanos , Vacinas Antimaláricas/administração & dosagem , Vacinas Antimaláricas/efeitos adversos , Malária Falciparum/imunologia , Masculino , VacinaçãoRESUMO
Controlled human malaria infection (CHMI) is a powerful tool to evaluate the efficacy of malaria vaccines and pharmacologics. Investigators at the University of Maryland, Baltimore, Center for Vaccine Development (UMB-CVD) pioneered the technique in the 1970s and continue to advance the frontiers of CHMI research. We reviewed the records of 338 malaria-naive volunteers who underwent CHMI at UMB-CVD with Plasmodium falciparum from 1971 until 2017. These 338 volunteers underwent 387 CHMI events, including 60 via intradermal injection or direct venous inoculation (DVI) of purified, cryopreserved sporozoites. No volunteer suffered an unplanned hospitalization or required intravenous therapy related to CHMI. Median prepatency period was longer in challenges using NF54 (9 days) than in those using 7G8 (8 days), P = 0.0006 by the log-rank test. With dose optimization of DVI, the prepatent period did not differ between DVI and mosquito bite challenge (log-rank test, P = 0.66). Polymerase chain reaction (PCR) detected P. falciparum infection 3 days earlier than thick smears (P < 0.001), and diagnosis by ultrasensitive PCR was associated with less severe symptoms than smear-based diagnosis (39% versus 0%, P = 0.0003). Historical studies with NF54 showed a shorter median prepatency period of 10.3 days than more recent studies (median 11.0 days, P = 0.02) despite significantly lower salivary gland scores in earlier studies, P = 0.0001. The 47-year experience of CHMI at UMB-CVD has led to advancements in sporozoite delivery, diagnostics, and use of heterologous challenge. Additional studies on new challenge strains and genomic data to reflect regional heterogeneity will help advance the use of CHMI as supporting data for vaccine licensure.
Assuntos
Malária Falciparum/parasitologia , Malária Falciparum/terapia , Voluntários , Adulto , Humanos , Mordeduras e Picadas de Insetos , Vacinas Antimaláricas/uso terapêutico , Malária Falciparum/transmissão , Parasitemia , EsporozoítosRESUMO
BACKGROUND: Highly sensitive, scalable diagnostic methods are needed to guide malaria elimination interventions. While traditional microscopy and rapid diagnostic tests (RDTs) are suitable for the diagnosis of symptomatic malaria infection, more sensitive tests are needed to screen for low-density, asymptomatic infections that are targeted by interventions aiming to eliminate the entire reservoir of malaria infection in humans. METHODS: A reverse transcription polymerase chain reaction (RT- PCR) was developed for multiplexed detection of the 18S ribosomal RNA gene and ribosomal RNA of Plasmodium falciparum and Plasmodium vivax. Simulated field samples stored for 14 days with sample preservation buffer were used to assess the analytical sensitivity and specificity. Additionally, 1750 field samples from Southeastern Myanmar were tested both by RDT and ultrasensitive RT-PCR. RESULTS: Limits of detection (LoD) were determined under simulated field conditions. When 0.3 mL blood samples were stored for 14 days at 28 °C and 80% humidity, the LoD was less than 16 parasites/mL for P. falciparum and 19.7 copies/µL for P. vivax (using a plasmid surrogate), about 10,000-fold lower than RDTs. Of the 1739 samples successfully evaluated by both ultrasensitive RT-PCR and RDT, only two were RDT positive while 24 were positive for P. falciparum, 108 were positive for P. vivax, and 127 were positive for either P. vivax and/or P. falciparum using ultrasensitive RT-PCR. CONCLUSIONS: This ultrasensitive RT-PCR method is a robust, field-tested screening method that is vastly more sensitive than RDTs. Further optimization may result in a truly scalable tool suitable for widespread surveillance of low-level asymptomatic P. falciparum and P. vivax parasitaemia.
Assuntos
Infecções Assintomáticas , Sangue/parasitologia , Malária Falciparum/diagnóstico , Malária Vivax/diagnóstico , Plasmodium falciparum/isolamento & purificação , Plasmodium vivax/isolamento & purificação , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , DNA de Protozoário/genética , DNA Ribossômico/genética , Humanos , Mianmar , Plasmodium falciparum/genética , Plasmodium vivax/genética , RNA de Protozoário/genética , RNA Ribossômico 18S/genética , Sensibilidade e EspecificidadeRESUMO
Controlled human malaria infection (CHMI) is a powerful tool to evaluate malaria vaccine and prophylactic drug efficacy. Until recently CHMI was only carried out by the bite of infected mosquitoes. A parenteral method of CHMI would standardize Plasmodium falciparum sporozoite (PfSPZ) administration, eliminate the need for expensive challenge facility infrastructure, and allow for use of many P. falciparum strains. Recently, intradermal (ID) injection of aseptic, purified, cryopreserved PfSPZ was shown to induce P. falciparum malaria; however, 100% infection rates were not achieved by ID injection. To optimize ID PfSPZ dosing so as to achieve 100% infection, 30 adults aged 18-45 years were randomized to one of six groups composed of five volunteers each. The parameters of dose (1 × 10(4) versus 5 × 10(4) PfSPZ total dose per volunteer), number of injections (two versus eight), and aliquot volume per ID injection (10 µL versus 50 µL) were studied. Three groups attained 100% infection: 1 × 10(4) PfSPZ in 50 µL/2 doses, 1 × 10(4) PfSPZ in 10 µL/2 doses, and 5 × 10(4) PfSPZ in 10 µL/8 doses. The group that received 5 × 10(4) PfSPZ total dose in eight 10 µL injections had a 100% infection rate and the shortest prepatent period (mean of 12.7 days), approaching the prepatent period for the current CHMI standard of five infected mosquitoes.
Assuntos
Malária Falciparum/parasitologia , Plasmodium falciparum/fisiologia , Esporozoítos/fisiologia , Adulto , Anticorpos Antiprotozoários/sangue , Anticorpos Antiprotozoários/imunologia , Antimaláricos/uso terapêutico , Cloroquina/análogos & derivados , Cloroquina/uso terapêutico , Criopreservação , Feminino , Humanos , Injeções Intradérmicas , Malária Falciparum/tratamento farmacológico , Malária Falciparum/etiologia , Malária Falciparum/imunologia , Masculino , Segurança do Paciente , Plasmodium falciparum/imunologia , Esporozoítos/imunologia , Adulto JovemRESUMO
BACKGROUND: Both Plasmodium vivax and Plasmodium falciparum are prevalent in Pakistan, yet up-to-date data on the epidemiology of malaria in Pakistan are not available. This study was undertaken to determine the current prevalence and distribution of Plasmodium species across the country. METHODS: A malariometric population survey was conducted in 2011 using blood samples collected from 801 febrile patients of all ages in four provinces and the capital city of Islamabad. Microscopically confirmed Plasmodium-positive blood samples were reconfirmed by polymerase chain reaction (PCR). Confirmed parasite-positive samples were subjected to species-specific PCR capable of detecting four species of human malaria. RESULTS: Of the 707 PCR-positive samples, 128 (18%) were P. falciparum, 536 (76%) were P. vivax, and 43 (6%) were mixed P. falciparum and P. vivax. Ninety-four microscopy-positive samples were PCR-negative, and Plasmodium malariae and Plasmodium ovale were not detected. Prevalence of P. vivax ranged from 2.4% in Punjab Province to 10.8% in Sindh Province and prevalence of P. falciparum ranged from 0.1% in Islamabad to 3.8% in Balochistan. CONCLUSIONS: Plasmodium infections in Pakistan are largely attributed to P. vivax but P. falciparum and mixed species infections are also prevalent. In addition, regional variation in the prevalence and species composition of malaria is high.
Assuntos
Malária/epidemiologia , Malária/parasitologia , Plasmodium/classificação , Plasmodium/isolamento & purificação , Adolescente , Adulto , Idoso , Sangue/parasitologia , Criança , Pré-Escolar , Coleta de Dados , Feminino , Humanos , Lactente , Masculino , Microscopia , Pessoa de Meia-Idade , Paquistão/epidemiologia , Reação em Cadeia da Polimerase , Prevalência , Adulto JovemRESUMO
The Mandatory Guidelines for Federal Workplace Drug Testing Programs provide criteria for specimen validity testing, including urine pH cut-offs, to report a urine specimen as adulterated or invalid. Since the urine pH criteria for invalid classifications, > or = 3 and < 4.5 or > or = 9 and < 11, became effective in November 2004, a number of specimens with results within the upper invalid limits, typically in the range of 9.1 to 9.3, have been reported with no evidence of adulteration. This study evaluated the hypothesis that these pH findings were the result of exposure to increased environmental temperatures during specimen standing and transport. Indeed, increased storage temperatures were associated with increased urine pH, with the magnitude of the change related to both storage time and temperature. The pH values of specimens stored at -20 degrees C are relatively stable, whereas pH results > 9 are achieved at storage temperatures of room temperature or higher. It is noteworthy that no condition(s) produced a specimen with a pH > 9.5. Degradation of nitrogenous urine analytes is most likely responsible for the noted increases in pH. These findings are intended to supplement information used by the Medical Review Officers who are responsible for interpreting such marginally invalid pH results.
Assuntos
Temperatura Alta , Drogas Ilícitas/urina , Manejo de Espécimes/métodos , Detecção do Abuso de Substâncias/métodos , Urinálise , Urina/química , Estabilidade de Medicamentos , Humanos , Concentração de Íons de Hidrogênio , Valores de Referência , Fatores de TempoRESUMO
OBJECTIVES: Novel comparison of CDT isoforms as determined by CE with an FDA-approved immunoassay kit. DESIGN AND METHODS: Subjects (n=51) were categorized by drinking status based on AUDIT questionnaire responses. CDT isoform analyses by CE were compared to a commercially available, FDA-approved immunoassay. The analytical specificity of the immunoassay kit was assessed by analysis with IEF. RESULTS: Because of the poor correlation between % CDT as measured by CE and the TIA immunoassay and between subject-reported drinking levels and results from the TIA assay, extraction column eluants from the immunoassays were analyzed by IEF for analytical specificity. % CDT by TIA included some trisialo-Tf, a non-CDT fraction, in the % CDT determination. CONCLUSIONS: Total % CDT by CE, which separates all isoforms is more analytically specific than immunoassays because it does not include trisialo-Tf in the CDT calculation.
Assuntos
Eletroforese Capilar/métodos , Imunoensaio/métodos , Transferrina/análogos & derivados , Adolescente , Adulto , Feminino , Humanos , Focalização Isoelétrica , Masculino , Pessoa de Meia-Idade , Transferrina/análiseRESUMO
Vibrio vulnificus is the leading cause of death in the United States associated with the consumption of raw seafood, particularly oysters. In epidemiological studies, primary septicemia and inflammation-mediated septic shock caused by V. vulnificus is strongly associated with liver disease, often in the context of chronic alcohol abuse. The present study was undertaken to determine whether clinical biomarkers of liver function or cellular oxidative stress are associated with peripheral blood mononuclear cell inflammatory cytokine responses to V. vulnificus. Levels of interleukin-1 beta (IL-1 beta), IL-6, IL-8, and tumor necrosis factor alpha elicited in response to V. vulnificus and measured in cell supernatants were not associated with the liver biomarkers aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or the AST/ALT ratio. In contrast, reduced glutathione (GSH) levels were associated with the release of all four cytokines (IL-1 beta [R(2) = 0.382; P = 0.006], IL-6 [R(2) = 0.393; P = 0.005], IL-8 [R(2) = 0.487; P = 0.001], and TNF-alpha [R(2) = 0.292; P = 0.021]). Those individuals with below-normal GSH levels produced significantly less proinflammatory cytokines in response to V. vulnificus. We hypothesize that persons with markers for cellular oxidative stress have increased susceptibility to V. vulnificus septicemia.